Skip to Main Content
Important information:
Please click here to get the facts about the COVID-19 vaccine.

Program

Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition

PROGRAM
All Times are EST
Program is subject to change

Friday, February 12, 2021

7:50 am Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD
  Session I: Imaging Normal and Non-Exudative AMD Eyes
Moderators: Philip J. Rosenfeld, MD, PhD; Zohar Yehoshua, MD, MHA; Giovanni Gregori, PhD
Panelists: Christine A. Curcio, PhD; James G. Fujimoto, PhD; Ruikang (Ricky) Wang, PhD; Eric M. Moult, BSc; Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS; David Sarraf, MD
8:00 Histopathology of Basal Laminar Deposits and Bruch’s Membrane in AMD
Christine A. Curcio, PhD

8:15 Ultrahigh Resolution SD-OCT in Normal Aging and AMD
James G. Fujimoto, PhD

8:30 Quantitative Measurements of 3D Choroid and Choriocapillaris Using SS-OCT
Ruikang (Ricky) Wang, PhD
8:45 Computational Modelling for Assessing OCT Biomarkers of Geographic Atrophy Growth
Eric M. Moult, BSc
9:00 The Status of the Choriocapillaris in Nascent GA
Robyn Guymer, MBBS, PhD, FRANZCO, FAHMS
9:15 Rate of Progression of iRORA to cRORA in AMD
David Sarraf, MD

9:30 En Face OCT Imaging Simplifies the Detection of Pre-cRORA Lesions
Philip J. Rosenfeld, MD, PhD

  Session II: Imaging Eyes With Exudative AMD
Moderators: Thomas A. Albini, MD; Luis J. Haddock, MD; Raquel Goldhardt, MD
Panelists: Seung-Young Yu, MD; Usha Chakravarthy, MD; K. Bailey Freund, MD; Anat Loewenstein, MD
9:45 OCTA Biomarkers for CNV Secondary to AMD
Seung-Young Yu, MD

10:00 Detection of Exudative AMD at Earliest Onset Yields New Information on Lesion Morphology
Usha Chakravarthy, MD

10:15 Multimodal Imaging Features and Clinical Relevance of Subretinal Lipid Globules
K. Bailey Freund, MD

10:30 Home OCT Based Management of Neovascular AMD
Anat Loewenstein, MD

  Session III: Emerging Therapies for Non-Exudative AMD
Moderators: Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; Nicolas Yannuzzi, MD
Panelists: Nadia K. Waheed, MD, MPH; Jeffrey S. Heier, MD; Charles C. Wykoff, MD, PhD; Pravin U. Dugel, MD; Cedric G. Francois, MD, PhD; Glenn J. Jaffe, MD; SriniVas R. Sadda, MD
10:45 Results of a Phase 1/2 Study on Gene Therapy for the Treatment of Geographic Atrophy
Nadia K. Waheed, MD, MPH

11:00 C5 Inhibition With Avacincaptad Pegol for the Treatment of Geographic Atrophy
Pravin U. Dugel, MD

11:15 Inhibition of Complement C3 in Geographic Atrophy With NGM621: Phase 1 Study Results
Charles C. Wykoff, MD, PhD

11:30 C3 Inhibition with Pegcetacoplan for the Treatment of GA in AMD
Cedric G. Francois, MD, PhD

11:45 Is it Valid to Use CAM OCT Criteria for Macular Atrophy in Interventional Non-Neovascular and Neovascular AMD Clinical Trials?
Glenn J. Jaffe, MD

12:00 pm Impact of Pegcetocoplan on Progression of Nascent Atrophy in AMD
SriniVas R. Sadda, MD

12:15 Update on Elamipretide for the Treatment of AMD
Jeffrey S. Heier, MD

12:30 Adjourn until Saturday Feb. 13th at 8:00 am

Saturday, February 13, 2021

7:50 am Welcome and Overview
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Thomas A. Albini, MD
  Session IV: Emerging Therapies for Exudative AMD
Moderators: Thomas A. Albini, MD; Jorge A. Fortun, MD; Sander R. Dubovy, MD
Panelists: Fenghua Wang, MD; David M. Brown, MD; Diana V. Do, MD; Carl D. Regillo, MD
8:00 The Efficacy and Safety of IBI 302, a Bispecific Antibody for the Treatment of Exudative AMD
Fenghua Wang, MD

8:15 Axitinib— A Novel TKI Delivered by Suprachoroidal Injection for AMD
David M. Brown, MD
8:30 KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases
Diana V. Do, MD
8:45 Port Delivery System (PDS) for Exudative AMD: Archway Phase 3 Study Results
Carl D. Regillo, MD
9:00 Brolucizumab Inflammation Update
Thomas A. Albini, MD

  Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy
Moderators: Janet Davis, MD; Ninel Z. Gregori, MD; Philip J. Rosenfeld, MD, PhD
Panelists: Allen Ho, MD; Arshad Khanani, MD, MA; Peter A. Campochiaro, MD
9:15 Subretinal Gene Therapy for Exudative AMD
Allen C. Ho, MD

9:30 Intravitreal Gene Therapy for Exudative AMD and Diabetic Retinopathy
Arshad Khanani, MD, MA

9:45 Suprachoroidal Gene Therapy for Exudative AMD and Diabetic Retinopathy
Peter A. Campochiaro, MD

  Session VI: Dual Inhibition of Ang2 and VEGF for the Treatment of DME and Exudative AMD – An Update from the Faricimab Program
Moderators: Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; Usha Chakravarthy, MD; Lawrence J. Singerman, MD
Panelists: Karl G. Csaky, MD, PhD; Jeffrey S. Heier, MD; Charles C. Wykoff, MD, PhD
10:00 Dual Inhibition of Ang-2 and VEGF-A with Faricimab: Rationale for Ang2 Inhibition in Exudative AMD and Diabetic Macular Edema
Karl G. Csaky, MD, PhD

10:15 Faricimab Phase 3 Topline Results in Diabetic Macular Edema
Charles C. Wykoff, MD, PhD

10:30 Faricimab Phase 3 Topline Results in Exudative AMD
Jeffrey S. Heier, MD

10:45 Discussion
  Session VII: Diabetes, Choroiditis, Retinitis Pigmentosa and Late Breaking Reports
Moderators: Harry W. Flynn, Jr., MD; Justin H. Townsend, MD; Jayanth Sridhar, MD
Panelists: Quan Dong Nguyen, MD, MSc; Jennifer K. Sun, MD; Dilsher S. Dhoot, MD; Lawrence A. Yannuzzi, MD; David S. Boyer, MD; Andrew A. Moshfeghi, MD, MBA
11:00 AXT-107: Potential Role in Neovascular AMD, Diabetic Macular Edema, and Retinal Vein Occlusion
Quan Dong Nguyen, MD, MSc

11:15 Widefield SS-OCT Imaging of Diabetic Retinopathy
Harry W. Flynn, Jr., MD

11:30 Anti-VEGF in the Treatment of Nonproliferative Diabetic Retinopathy
Jennifer K. Sun, MD

11:45 Correlation Between Baseline Retinal Non-Perfusion Area and Outcomes in the PANORAMA Study
Dilsher S. Dhoot, MD

12:00 pm Are There Two Forms of Multiple Evanescent White Dot Syndrome (MEWDS)?
Lawrence A. Yannuzzi, MD

12:15 Retinal Progenitor Cell Injections for Retinitis Pigmentosa
David S. Boyer, MD

12:30 Intravitreal Hydrogel-Based Axitinib Implant (OTX-TKI) for the Treatment of Neovascular AMD: Phase 1 Trial Update
Andrew A. Moshfeghi, MD, MBA

12:45 Post-Program Test and Closing Remarks